Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunosuppressive treatment in multiple sclerosis.

Howard L Weiner1

  • 1Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women's Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA. hweiner@rics.bwh.harvard.edu

Journal of the Neurological Sciences
|July 21, 2004
PubMed
Summary

Immunosuppressive therapies are effective for inflammatory multiple sclerosis (MS) stages, particularly when other treatments fail. Cyclophosphamide shows selective immune modulation, suppressing Th1 and enhancing Th2/Th3 responses in MS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What defines response to vagus nerve stimulation in children with drug-resistant epilepsy? A prospective cohort study from the CONNECTiVOS collaboration.

Epilepsia·2025
Same author

Society of MYND (Mentorship of Young Neurosurgical Doctors): a project for the ongoing education of junior faculty pediatric neurosurgeons.

Journal of neurosurgery. Pediatrics·2025
Same author

Common AAV gene therapy vectors show nonselective transduction of <i>ex vivo</i> human brain tissue.

Molecular therapy. Methods & clinical development·2025
Same author

Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Dampening of Microglial Activation With Nasal Foralumab Administration in Moderate Alzheimer's Disease Dementia.

Clinical nuclear medicine·2025
Same author

Faecal mucoprotein MUC2 is decreased in multiple sclerosis and is associated with mucin degrading bacteria.

EBioMedicine·2025

Area of Science:

  • Immunology
  • Neurology
  • Pharmacology

Background:

  • Immunosuppressive therapy has been a cornerstone in multiple sclerosis (MS) treatment for over three decades, predicated on the understanding of MS as a T cell-mediated autoimmune disorder.
  • Commonly utilized agents include azathioprine, cyclophosphamide, methotrexate, and mitoxantrone, often employed as combination therapy or monotherapy when first-line treatments like interferons and glatiramer acetate prove insufficient.

Discussion:

  • Immunosuppressants, similar to interferons and glatiramer acetate, demonstrate maximal efficacy in inflammatory stages of MS, characterized by relapses and MRI-detected gadolinium-enhancing lesions.
  • Their effectiveness is limited to earlier disease stages where inflammation overshadows central nervous system degenerative processes, with no proven benefit in primary progressive MS or late-stage secondary progressive MS.

Key Insights:

Related Experiment Videos

  • Cyclophosphamide, while a broad immunosuppressant, exhibits selective immunomodulatory effects in MS.
  • It specifically suppresses Interleukin-12 (IL-12) and T-helper 1 (Th1) responses while concurrently enhancing T-helper 2/3 (Th2/Th3) responses, including IL-4, IL-10, and transforming growth factor-beta (TGF-beta).
  • Peripheral blood eosinophil counts are also influenced by cyclophosphamide treatment.

Outlook:

  • Cyclophosphamide and mitoxantrone remain crucial for managing rapidly progressing MS cases unresponsive to beta-interferon or glatiramer acetate.
  • Further research into the selective immune-modulating properties of these agents could refine therapeutic strategies for specific MS phenotypes.